There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galmed Pharmaceuticals (GLMD) and ADMA Biologics (ADMA) with bullish sentiments.
Galmed Pharmaceuticals (GLMD)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galmed Pharmaceuticals today and set a price target of $28. The company’s shares closed yesterday at $8.44, close to its 52-week low of $4.84.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 9.3% and a 42.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on Galmed Pharmaceuticals is a Strong Buy with an average price target of $33.75, representing a 299.9% upside. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $59 price target.
See today’s analyst top recommended stocks >>
ADMA Biologics (ADMA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ADMA Biologics, with a price target of $10. The company’s shares closed yesterday at $3.89.
Selvaraju commented:
“We value ADMA via discounted cash flow (DCF)- based analysis, which models four principal lines of business (Nabi- HB, plasma reselling from ADMA’s own plasma center, BIVIGAM and RI-002). We apply a 10% discount rate and 30% effective tax rate, along with a 2.5% terminal growth rate.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.3% and a 37.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on ADMA Biologics is a Strong Buy with an average price target of $11.25, a 189.2% upside from current levels. In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
